Immunotherapy
Lung Cancer
EDU 35 - (INTERACTIVE) New Combinations of Radiation and Systemic Therapies in Lung Cancer: Chemotherapy, Targeted Agents and Immunotherapy
10/24/2018
7:45 AM - 9:00 AM
Location: Room 006
Session Type: Educational
1.25 AMA PRA Category 1 Credits™
1.25 CAMPEP Credits
1.50 MDCB Credits
Recent advances in radiation therapy techniques and the success of new systemic therapies, such as targeted agents and immunotherapy, have improved outcomes for many patients with lung cancer. Despite these successes, the efficacy and safety of combining radiation with newer systemic agents, including in patients receiving SBRT or hypofractionation, remain an active area of investigation.
This session will review the current state of knowledge on combining systemic agents, including chemotherapy, targeted agents, and immunotherapy, with conventional and hypofractionated radiation. The faculty will also discuss ongoing and proposed studies on this topic.
Following the session, attendees should be able to identify new systemic therapies for lung cancer, to discuss how these therapies can affect radiation planning and treatment, toxicities, and cancer outcomes, and to apply this knowledge when evaluating treatment options and making treatment decisions for their patients.
Learning Objectives:
- Describe new systemic therapies being used/investigated for lung cancer patients.
- Assess potential benefits and risks of combining systemic therapies (chemotherapy, targeted agents, immunotherapy) with radiation (conventional, hypofractionated).
- Apply knowledge of combining systemic therapies and radiation to the care of lung cancer patients.
Presentations:
7:45 AM - 8:03 AM
Overview: Using RT with systemic therapies in lung cancer
Speaker: – Dana-Farber Cancer Institute
8:03 AM - 8:21 AM
Chemotherapy and hypofractionated radiation
Speaker:
8:21 AM - 8:39 AM
Targeted therapies and radiation
Speaker: – Stanford University
8:39 AM - 8:57 AM
Immunotherapy and radiation
Speaker:
8:57 AM - 9:00 AM
Audience Q&A
Speaker: – Dana-Farber Cancer Institute